Lupin unveils Cyanocobalamin Nasal Spray in US
It is indicated for prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements more than normal.
Mumbai: Pharma major Lupin Limited has announced the launch of Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device), after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device) is a generic equivalent of Nascobal Nasal Spray, 500 mcg/spray of Par Pharmaceutical, Inc.
It is indicated for:
- vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement
- treatment of adult patients with dietary, drug-induced, or malabsorption related vitamin B12 deficiency not due to pernicious anemia
- prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements more than normal.
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 59 million in the U.S. (IQVIA MAT December 2023).
Read also: Lupin Gets CDSCO Panel Nod to Study FDC of Fluticasone, Glycopyrronium, Vilanterol Inhalation Powder
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers.
